Reply: Trazodone to change the risk of neurodegeneration: bedside to bench.
Published version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Halliday, Mark
Mallucci, Giovanna R
Abstract
We were interested to read the authors’ comments our recent paper in Brain (Halliday et al., 2017). We agree that carefully designed phase II and phase III trials would be needed to test the efficacy of trazodone as a treatment for neurodegeneration before use in human patients. However, it is also important to not underestimate the, potentially very significant, savings in both time and money that repurposing allows by skipping not only phase I trials, but also the arduous preclinical biochemistry, pharmacology, toxicology and medicinal chemistry needed for novel lead compounds. Hence, we do not feel we have overstated the potential of drug repurposing: there is an excellent premise for this in cancer, pain and other areas
Description
Keywords
Animals, Eukaryotic Initiation Factor-2, Mice, Protein Processing, Post-Translational, Proteomics, Trazodone
Journal Title
Brain
Conference Name
Journal ISSN
0006-8950
1460-2156
1460-2156
Volume Title
140
Publisher
Oxford University Press (OUP)
Publisher DOI
Sponsorship
Alzheimer's Drug Discovery Foundation (20141103)
European Research Council (647479)
European Research Council (647479)